Leslie A Enane1, Paul A Gastañaduy2, David M Goldfarb3, Jeffrey M Pernica4, Margaret Mokomane5, Banno Moorad6, Lingani Masole6, Jacqueline E Tate2, Umesh D Parashar2, Andrew P Steenhoff7. 1. Division of Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, Pennsylvania Botswana-UPenn Partnership, Gaborone, Botswana. 2. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Botswana-UPenn Partnership, Gaborone, Botswana Division of Microbiology, Department of Pathology, University of British Columbia, Vancouver, Canada Department of Pediatrics, University of Botswana, Gaborone Division of Infectious Disease, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. 4. Botswana-UPenn Partnership, Gaborone, Botswana Division of Infectious Disease, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. 5. National Health Laboratory, Gaborone, Botswana. 6. Botswana-UPenn Partnership, Gaborone, Botswana. 7. Botswana-UPenn Partnership, Gaborone, Botswana Department of Pediatrics, University of Botswana, Gaborone Division of Infectious Diseases and Section of Global Health, Department of Pediatrics, Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia.
Abstract
BACKGROUND: A monovalent human rotavirus vaccine (RV1) was introduced in Botswana in July 2012. We assessed the impact of RV1 vaccination on childhood gastroenteritis-related hospitalizations and deaths in 2013 and 2014. METHODS: We obtained data from registers of 4 hospitals in Botswana on hospitalizations and deaths from gastroenteritis, regardless of cause, among children <5 years of age. Gastroenteritis hospitalizations and deaths during the prevaccine period (January 2009-December 2012) were compared to the postvaccine period (January 2013-December 2014). Vaccine coverage was estimated from data collected through a concurrent vaccine effectiveness study at the same hospitals. RESULTS: By December 2014, coverage with ≥1 dose of RV1 was an estimated 90% among infants <1 year of age and 76% among children 12-23 months of age. In the prevaccine period, the annual median number of gastroenteritis-related hospitalizations in children <5 years of age was 1212, and of gastroenteritis-related deaths in children <2 years of age was 77. In the postvaccine period, gastroenteritis-related hospitalizations decreased by 23% (95% confidence interval [CI], 16%-29%) to 937, and gastroenteritis-related deaths decreased by 22% (95% CI, -9% to 44%) to 60. Declines were most prominent during the rotavirus season (May-October) and among infants <1 year of age, with reductions of 43% (95% CI, 34%-51%) in gastroenteritis hospitalizations and 48% (95% CI, 11%-69%) in gastroenteritis deaths. CONCLUSIONS: Following introduction of RV1 into the national immunization program, significant declines in hospitalizations and deaths from gastroenteritis were observed among children in Botswana, suggestive of the beneficial public health impact of rotavirus vaccination.
BACKGROUND: A monovalent human rotavirus vaccine (RV1) was introduced in Botswana in July 2012. We assessed the impact of RV1 vaccination on childhood gastroenteritis-related hospitalizations and deaths in 2013 and 2014. METHODS: We obtained data from registers of 4 hospitals in Botswana on hospitalizations and deaths from gastroenteritis, regardless of cause, among children <5 years of age. Gastroenteritis hospitalizations and deaths during the prevaccine period (January 2009-December 2012) were compared to the postvaccine period (January 2013-December 2014). Vaccine coverage was estimated from data collected through a concurrent vaccine effectiveness study at the same hospitals. RESULTS: By December 2014, coverage with ≥1 dose of RV1 was an estimated 90% among infants <1 year of age and 76% among children 12-23 months of age. In the prevaccine period, the annual median number of gastroenteritis-related hospitalizations in children <5 years of age was 1212, and of gastroenteritis-related deaths in children <2 years of age was 77. In the postvaccine period, gastroenteritis-related hospitalizations decreased by 23% (95% confidence interval [CI], 16%-29%) to 937, and gastroenteritis-related deaths decreased by 22% (95% CI, -9% to 44%) to 60. Declines were most prominent during the rotavirus season (May-October) and among infants <1 year of age, with reductions of 43% (95% CI, 34%-51%) in gastroenteritis hospitalizations and 48% (95% CI, 11%-69%) in gastroenteritis deaths. CONCLUSIONS: Following introduction of RV1 into the national immunization program, significant declines in hospitalizations and deaths from gastroenteritis were observed among children in Botswana, suggestive of the beneficial public health impact of rotavirus vaccination.
Authors: Robert E Black; Simon Cousens; Hope L Johnson; Joy E Lawn; Igor Rudan; Diego G Bassani; Prabhat Jha; Harry Campbell; Christa Fischer Walker; Richard Cibulskis; Thomas Eisele; Li Liu; Colin Mathers Journal: Lancet Date: 2010-05-11 Impact factor: 79.321
Authors: K Zaman; Duc Anh Dang; John C Victor; Sunheang Shin; Md Yunus; Michael J Dallas; Goutam Podder; Dinh Thiem Vu; Thi Phuong Mai Le; Stephen P Luby; Huu Tho Le; Michele L Coia; Kristen Lewis; Stephen B Rivers; David A Sack; Florian Schödel; A Duncan Steele; Kathleen M Neuzil; Max Ciarlet Journal: Lancet Date: 2010-08-06 Impact factor: 79.321
Authors: Henry Welch; Andrew P Steenhoff; Unoda Chakalisa; Tonya Arscott-Mills; Loeto Mazhani; Margaret Mokomane; Sara Foster-Fabiano; Kathleen E Wirth; Andrew Skinn; Jeffrey M Pernica; Marek Smieja; David M Goldfarb Journal: Pediatr Infect Dis J Date: 2013-05 Impact factor: 2.129
Authors: Li Liu; Hope L Johnson; Simon Cousens; Jamie Perin; Susana Scott; Joy E Lawn; Igor Rudan; Harry Campbell; Richard Cibulskis; Mengying Li; Colin Mathers; Robert E Black Journal: Lancet Date: 2012-05-11 Impact factor: 79.321
Authors: Shabir A Madhi; Nigel A Cunliffe; Duncan Steele; Desirée Witte; Mari Kirsten; Cheryl Louw; Bagrey Ngwira; John C Victor; Paul H Gillard; Brigitte B Cheuvart; Htay H Han; Kathleen M Neuzil Journal: N Engl J Med Date: 2010-01-28 Impact factor: 91.245
Authors: Margaret Mokomane; Jacqueline E Tate; Andrew P Steenhoff; Mathew D Esona; Michael D Bowen; Kwana Lechiile; Jeffrey M Pernica; Ishmael Kasvosve; Umesh D Parashar; David M Goldfarb Journal: Pediatr Infect Dis J Date: 2018-03 Impact factor: 2.129
Authors: Nicole L Davis; Jeffrey Wiener; Jonathan J Juliano; Linda Adair; Charles S Chasela; Dumbani Kayira; Michael G Hudgens; Charles van der Horst; Denise J Jamieson; Athena P Kourtis Journal: Clin Infect Dis Date: 2017-08-15 Impact factor: 9.079
Authors: Morgan Congdon; Hwanhee Hong; Rebecca R Young; Coleen K Cunningham; Leslie A Enane; Tonya Arscott-Mills; Francis M Banda; Mamiki Chise; Keneilwe Motlhatlhedi; Kristen Feemster; Sweta M Patel; Sefelani Boiditswe; Tiroyaone Leburu; Samir S Shah; Andrew P Steenhoff; Matthew S Kelly Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Shahin Lockman; Michael Hughes; Kate Powis; Gbolahan Ajibola; Kara Bennett; Sikhulile Moyo; Erik van Widenfelt; Jean Leidner; Kenneth McIntosh; Loeto Mazhani; Joseph Makhema; Max Essex; Roger Shapiro Journal: Lancet Glob Health Date: 2017-05 Impact factor: 26.763
Authors: Christabel C Enweronu-Laryea; George Armah; Kwamena W Sagoe; Daniel Ansong; Emmanuel Addo-Yobo; Stanley K Diamenu; Jason M Mwenda; Umesh D Parashar; Jacqueline E Tate Journal: Vaccine Date: 2018-05-08 Impact factor: 3.641
Authors: Syed M Satter; Negar Aliabadi; Paul A Gastañaduy; Warda Haque; Abdullah Mamun; Meerjady S Flora; K Zaman; Mustafizur Rahman; James D Heffelfinger; Stephen P Luby; Emily S Gurley; Umesh D Parashar Journal: Vaccine Date: 2018-05-21 Impact factor: 4.169
Authors: Amadou Diop; Aliou Thiongane; Jason M Mwenda; Negar Aliabadi; Mouhamadou A Sonko; Aliou Diallo; Babacar Ndoye; Papa M Faye; Idrissa D Ba; Umesh D Parashar; Jacqueline E Tate; Ousmane Ndiaye; Moussa F Cissé; Mamadou Ba Journal: Vaccine Date: 2017-11-20 Impact factor: 3.641